4//SEC Filing
Aquilo Capital, L.P. 4
Accession 0001591986-22-000010
CIK 0001701108other
Filed
Feb 22, 7:00 PM ET
Accepted
Feb 23, 4:24 PM ET
Size
8.0 KB
Accession
0001591986-22-000010
Insider Transaction Report
Form 4
Aquilo Capital, L.P.
10% Owner
Transactions
- Purchase
Common Stock, $0.001 par value
2022-02-18$9.24/sh+14,828$137,039→ 5,162,963 total(indirect: See Footnotes)
Aquilo Capital Management, LLC
10% Owner
Transactions
- Purchase
Common Stock, $0.001 par value
2022-02-18$9.24/sh+14,828$137,039→ 5,162,963 total(indirect: See Footnotes)
Footnotes (2)
- [F1]The reporting persons are Aquilo Capital, L.P. (the "Fund"), Aquilo Capital Management, LLC ("Aquilo") and Marc R. Schneidman. Aquilo is the general partner and investment adviser of the Fund and other funds managed by Aquilo that hold securities directly for the benefit of their investors. Aquilo may be deemed to beneficially own such securities indirectly as the investment adviser and general partner of the Fund and affiliated funds, and Mr. Schneidman may be deemed to beneficially own them indirectly as the control person of Aquilo. Each of, Aquilo, the Fund and Mr. Schneidman disclaims beneficial ownership of such securities except to the extent of his or its pecuniary interest therein.
- [F2]Aquilo Capital, LP owns 3,393,709 of the 5,162,963 shares deemed to be beneficially owned by Aquilo Capital Management, LLC. Aquilo Capital, LP purchased 14,828 shares in this transaction on 2/18/2022.
Documents
Issuer
Spero Therapeutics, Inc.
CIK 0001701108
Entity typeother
IncorporatedDE
Related Parties
1- filerCIK 0001491371
Filing Metadata
- Form type
- 4
- Filed
- Feb 22, 7:00 PM ET
- Accepted
- Feb 23, 4:24 PM ET
- Size
- 8.0 KB